** Shares of cell therapy developer BioCardia more than doubles to $4.42 premarket
** Company says the U.S. FDA has cleared its device used in heart procedures
** The device, called a Morph DNA Steerable Introducer, is designed to provide a pathway to introduce medical instruments such as catheters into the heart - BCDA
** The clearance covers 16 products in the category of devices - BCDA
** If gains hold, stock set to erase YTD losses of ~78%
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments